课题基金 / 基金详情

Hypercytokinemia a underlies the morbid condition of sepsis.

Hypercytokinemia a underlies the morbid condition of sepsis.
高细胞因子血症是败血症病态的基础。
批准号:
15390547
负责人:
ENDO Shigeatsu
金额:
$7.1万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2004

项目摘要

项目成果

ENDO Shigeatsu的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
In sepsis, inflammatory cytokines are produced as a local or systemic reaction, and cytokines produced locally act on distant organs. Cytokines are produced in abnormal quantities in the presence of sepsis. Cytokine production is controlled positively and negatively, and abnormal production is usually suppressed. However, when cytokines are produced in abnormal quantities as a result of a disorder of control, irreversible morbid conditions including ARDS, DIC and sepsis are induced. The most severe morbid condition is septic shock. It often progresses to multiple organ failure, frequently leading to a fatal course. In this process, phospholipase A2, eicosanoid, nitrogen monoxide, endothelin-1, thrombomodulin, neutrophil elastase, adhesion molecules, and so on are produced in response to stimulation with cytokines. They induce cytotoxicity and tissue disorder directly or indirectly, thereby leading to complicated morbid conditions. It was confirmed that neutrophils play an important role in the secondary systemic response to sepsis. The observation indicates that activation of neutrophils fixes the course of systemic sepsis to establish conditions for the development of septic shock and multiple organ failure. Our future research tasks include phenomenological elucidation of details of the general secondary systemic response, acquisition of fundamental knowledge contributing to treatment of septic shock and multiple organ failure, and construction of a theory of infection control on the basis of changes in bio-reactivity.
期刊论文(53)
专著(0)
科研奖励(0)
会议论文
Yamada Y.et al.: "Examination of soluble Fas (sFas) and soluble fas ligand (sFasL) in patients with burns"Burns. 29. 799-802 (2003)
Yamada Y.等人:“烧伤患者中可溶性 Fas (sFas) 和可溶性 fas 配体 (sFasL) 的检查”烧伤。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Increase in the plasma nuclear mafrix protein(NMP)level in patients with septic multiple organ dysfunction syndrome associated eith generalized peritonitis
全身性腹膜炎相关脓毒症多器官功能障碍综合征患者血浆核基质蛋白(NMP)水平升高
DOI: --
发表时间: 2004
期刊: Medical Postgraduates 42
影响因子: --
作者: [Kitamura M, Endo S, Sato N, et al.]
通讯作者: et al.
遠藤 重厚 他: "ラテックス免疫比濁法による好中球エラスターゼ測定の評価"Progressive Medicine. 23. 2174-2176 (2003)
Shigetsu Endo 等人:“通过乳胶免疫比浊法评估中性粒细胞弹性蛋白酶测量”进步医学 23. 2174-2176 (2003)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Ueshima K.et al.: "Extracellular matrix disturbances in acute myocardial infarction : relation between disease severity and matrix metalloproteinase-1 and effects of magnesium"Magnesium Research. 16. 120-126 (2003)
Ueshima K.等人:“急性心肌梗塞中的细胞外基质紊乱:疾病严重程度与基质金属蛋白酶-1 和镁的影响之间的关系”镁研究。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
25
    Tecnological development of endotoxin assay with leukocyte-rich plasma and plasma in sepsis
    • 批准号:
      22390339
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.98万
    • 财政年份:
      2010
    • 负责人:
      ENDO Shigeatsu
    • 依托单位:
    The development of rapid infection diagnosis kit using soluble CD14 subtype
    • 批准号:
      19209056
    • 项目类别:
      Grant-in-Aid for Scientific Research (A)
    • 资助金额:
      $21.05万
    • 财政年份:
      2007
    • 负责人:
      ENDO Shigeatsu
    • 依托单位:
    Development of a new pretreatment method for plasma endotoxin assay
    国内基金
    海外基金
    KCTD10对2型免疫反应(Th2)的调控研究
    • 批准号:
      2020JJ4441
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2020
    • 负责人:
      任凯群
    • 依托单位:
    IL-6受体泛素化调控机制
    • 批准号:
      32070775
    • 项目类别:
      面上项目
    • 资助金额:
      58.0万元
    • 批准年份:
      2020
    • 负责人:
      李姝
    • 依托单位:
    乙烯合酶ACS家族的AEF蛋白调节拟南芥开花时间的机制研究
    • 批准号:
      31970735
    • 项目类别:
      面上项目
    • 资助金额:
      58.0万元
    • 批准年份:
      2019
    • 负责人:
      江静
    • 依托单位:
    USP13调控IL-18诱导的NF-κB活化的分子机制研究
    • 批准号:
      31900556
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      26.0万元
    • 批准年份:
      2019
    • 负责人:
      林恒
    • 依托单位: